T cell receptor (TCR) recognizing peptide–MHC class II complexes (TCR-pMHCII)

The T cell receptor (TCR) recognizing peptide–MHC class II (pMHCII) complexes is a specialized heterodimeric protein complex found on the surface of CD4+ T lymphocytes (UniProt, P01848). It consists of alpha and beta glycoprotein chains that work in conjunction with the CD3 signaling complex to recognize exogenous antigens presented by MHC class II molecules (HLA-DR, -DQ, -DP) on professional antigen-presenting cells (StatPearls, NBK541069). This recognition event is a cornerstone of the adaptive immune response, triggering T cell activation, proliferation, and differentiation into various helper T cell subsets (Nature Reviews Immunology, 2021). These subsets then coordinate immune activities, such as B cell maturation and the activation of cytotoxic T cells and macrophages (Janeway's Immunobiology, 9th Ed). In disease states, dysregulation of this interaction can lead to autoimmune disorders where the TCR recognizes self-peptides, or to immune evasion by tumors that downregulate MHC expression (Science Translational Medicine, 2022). Therapeutically, this target is exploited through TCR-engineered T cell (TCR-T) therapies, which equip a patient's T cells with specific TCRs designed to target MHCII-restricted tumor antigens (Journal for ImmunoTherapy of Cancer, 2020). Additionally, monoclonal antibodies like Teplizumab target the associated CD3 complex to inhibit TCR signaling, providing a treatment for autoimmune conditions like Type 1 Diabetes (FDA, 2022). Challenges in targeting this complex include the high polymorphism of MHCII alleles across the human population and the risk of off-target toxicity due to TCR cross-reactivity with similar endogenous peptides (Frontiers in Immunology, 2021).

Other names

MHC class II-restricted T cell receptorCD4+ T cell receptorTCR-MHCII complexAntigen-specific T cell receptorTCR-CD3 complex

Therapeutic agents targeting this complex either inhibit TCR-mediated signaling through the associated CD3 subunits to suppress autoimmune responses or utilize engineered TCR sequences to redirect T cells to recognize and eliminate cells presenting specific peptide-MHC class II antigens (PubMed, 33619385; FDA, 2022).